Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban

Clinical trial NCT01826266 · COMPLETED

Trial details

NCT number

NCT01826266

Sponsor

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.

Status

COMPLETED

Phase

Phase 1

Study type

INTERVENTIONAL

Start date

2013-07-01

Primary completion

2013-12-01

Enrollment

83

View on ClinicalTrials.gov